While SANG at the concentration of 5 mg/kg has demonstrated nephroprotective effects on CP-induced AKI in mice, further studies are required to evaluate its dose-response effects, along with its long-term safety and efficacy. This evidence concerns the gene GNAS-AS1 and acute kidney injury.